5一20扫雷群icer’s extension into non-drug assessments will have substantial implications for device, diagnostic and digital therapeutic innovators, as their new paradigm will allow for comparison of not only drugs against each other (or the natural history of disease), but also a comparison of products from different spaces within the life sciences industry. for example, also making their short list is a potential comparison of devices for atrial fibrillation compared to dabigatran.
those of you with experience working with icer likely already understand the importance of ensuring the data and model structure they use is reflective of your knowledge and expertise, which is critical to ensuring a favorable review. at boston healthcare, we regularly leverage our expertise in health economics to assist clients with health economic modeling and icer planning. to learn more about icer, what they are doing, and what this might mean for you, be sure to register for our upcoming webinar on wednesday, march 25 at 11am!